Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors

Pengxiang Yang1,2, Xiaomin Yao1, Xue Tian3

  • 1Key Laboratory of Neuroregeneration of Jiangsu Province and Ministry of Education, Co-Innovation Center of Neuroregeneration, NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products, Nantong University, 226001, Nantong, PR China.

Materials Today. Bio
|February 10, 2025
PubMed

Insights

This study developed a novel supramolecular peptide hydrogel epitope vaccine combined with CAR-T cells. This SPEV-CAR-T therapy enhances targeting efficiency and persistence, showing superior anti-tumor effects in solid tumors.

Area of Science:

  • Biomaterials Science
  • Immunotherapy
  • Oncology

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapy shows promise in hematological malignancies but faces challenges in solid tumors due to the tumor microenvironment.
  • Key limitations for CAR-T therapy in solid tumors include targeting efficiency and cell persistence.
  • Biomaterials offer a strategy to modulate immune responses and enhance CAR-T cell function.

Purpose of the Study:

  • To design a supramolecular peptide hydrogel epitope vaccine as a preparation medium and reservoir for CAR-T cells.
  • To investigate the efficacy of this combined system (SPEV-CAR-T) in improving anti-tumor responses against solid tumors.
  • To address the limitations of targeting efficiency and persistence in CAR-T therapy for solid tumors.

Main Methods:

  • A self-assembling peptide hydrogel was created using non-covalent interactions.
  • Complementary peptide-conjugated vaccine epitopes targeting HER2 were designed and combined with CAR-T cells.
  • The SPEV-CAR-T system was evaluated for its effects on CAR-T cell proliferation, cytotoxicity, and immune response induction in vitro and in vivo.

Main Results:

  • The epitope hydrogel promoted CAR-T cell proliferation, cytotoxic activity, and lymphocyte transformation.
  • SPEV-CAR-T induced endogenous humoral and cellular immune responses, demonstrating superior anti-tumor effects in a mouse model.
  • Crucially, SPEV-CAR-T induced central memory cells, improving the persistence of CAR-T therapy.

Conclusions:

  • The integrated supramolecular peptide hydrogel epitope vaccine and CAR-T system (SPEV-CAR-T) offers a novel approach for solid tumor treatment.
  • This all-in-one system facilitates sequential endogenous and exogenous immune responses for persistent and specific tumor attack.
  • SPEV-CAR-T demonstrates superior therapeutic potential for solid tumors by overcoming current CAR-T limitations.

Related Concept Videos